From GlobeNewswire: 2025-02-23 18:33:52

Mesoblast Limited has appointed Dr. Gregory George, its largest shareholder, to the Board of Directors. Dr. George’s operational experience and medical background will be valuable as Mesoblast transitions to a commercial organization. Mesoblast’s CEO, Dr. Silviu Itescu, sees Dr. George’s skills as crucial for the company’s growth. Dr. George is optimistic about Mesoblast’s potential to revolutionize healthcare with its mesenchymal stem cell technology. The company’s first FDA-approved therapy, RYONCIL®, is for pediatric patients with acute graft versus host disease. Mesoblast is also developing treatments for other inflammatory conditions and has a strong global intellectual property portfolio.



Read more at GlobeNewswire: Dr. Gregory George MD PhD Joins Mesoblast Board